The cutoff values associated with a PPV (for MOG-IgG associated with a clinical MOGAD phenotype) of ∼95% were ≥1:160 for MOG α1 (190/214 non-MS vs 11/164 controls), α3 (89/214 non-MS vs 4/164 controls), and β1 (185/214 non-MS vs 10/164 controls), ≥1:40 for MOG α2 (86/214 non-MS vs 5/164 controls) and β2 (52/214 non-MS vs 2/164 controls), and ≥1:80 for MOG β3 (58/214 non-MS vs 2/164 controls). This evidence concerns the gene MOG and myeloid sarcoma.